Findings

What do systematic reviews say?

28 questions · 40 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 18 · 45%Low 21 · 52.5%Moderate 1 · 2.5%High 0 · 0%

Summary of findings 2: Immunotherapies vs placebo

(1512) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1012 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1012 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(3774) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 4088 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 4118 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(3044) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3207 participants
Moderate
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3207 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(1935) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1294 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1294 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(543) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 404 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 404 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(4360) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2278 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2278 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(1941) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1334 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1334 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(295) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1153 participants
Low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1153 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(0) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1774 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2134) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1309 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1309 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(889) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1421 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1421 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2578) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1948 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(60) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(2169) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 4007 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(621) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1336 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1336 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(5032) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 4752 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(1003) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 533 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(242) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 182 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(2693) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 3886 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2601) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3615 participants
Low